In adults with persistent or recurrent type 2 diabetes after metabolic surgery, liraglutide lowered HbA1c more than placebo at 26 weeks.
In plain wordsIn adults whose type 2 diabetes remained or returned after weight-loss surgery, liraglutide lowered HbA1c more than placebo.
- Peptide
- Liraglutide
- Outcome
- DecreaseHbA1c change from baseline to 26 weeks
- Study
n = 71
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 1.8 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
- HbA1c difference vs placebo
- −13.3 mmol/mol
- 26 weeks
- HbA1c difference vs placebo
- −1.22%
- 26 weeks
Source sentences
In a multivariable linear regression analysis, with baseline HbA1c levels and surgery type as covariates, liraglutide treatment was associated with a difference of -13·3 mmol/mol (-1·22%, 95% CI -19·7 to -7·0; p=0·0001) in HbA1c change from baseline to 26 weeks, compared with placebo.
2 context sentences(design, population, supporting numbers)
In the GRAVITAS randomised double-blind, placebo-controlled trial, we enrolled adults who had undergone Roux-en-Y gastric bypass or vertical sleeve gastrectomy and had persistent or recurrent type 2 diabetes with HbA1c levels higher than 48 mmol/mol (6·5%) at least 1 year after surgery fr…
Participants were randomly assigned (2:1) via a computer-generated sequence to either subcutaneous liraglutide 1·8 mg once daily or placebo, both given together with a reduced-calorie diet, aiming for a 500 kcal per day deficit from baseline energy intake, and increased physical activity.